1 active not recruiting, 1 recruiting, 1 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow MAP2K1 Gene Mutation: new trials by email Literature Review of MAP2K1 Gene Mutation trials Research Report on MAP2K1 Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations Alpelisib, Mirdametinib - Slow-Flow Vascular Malformation, Fast-Flow Vascular Malformation | Phase 2 | Recruiting | Murdoch Childrens Research Institute | 50 | 2024-09-13 | 2026-05-05 |
| Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations Ulixertinib, Physician's Choice - Advanced Solid Tumor, BRAF Gene Mutation | Phase 2 | Terminated | BioMed Valley Discoveries, Inc | 104 | 2021-01-07 | 2024-06-04 |
| Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer Laboratory Biomarker Analysis, Panitumumab, Trametinib - EGFR NP_005219.2:p.S492R, KRAS Gene Mutation | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 59 | 2017-12-29 | 2026-07-16 |
Arteriovenous Malformations (1) · Colorectal Neoplasms (1) · Lymphangioma (1) · Lymphangioma, Cystic (1) · Lymphatic Abnormalities (1) · Skin Diseases, Vascular (1) · Vascular Malformations (1)
Neoplasms (2) · Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1) · Colonic Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Hemic and Lymphatic Diseases (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Lymphatic Diseases (1) · Neoplasm, Lymphatic Tissue (1)
Alpelisib (1) · Panitumumab (1) · mirdametinib (1) · trametinib (1) · ulixertinib (1)
BioMed Valley Discoveries, Inc (1) · M.D. Anderson Cancer Center (1) · Murdoch Childrens Research Institute (1)
United States (2) · Australia (1)
Christine Parseghian (1) · Lydia Pathmanathan, MBBS, FRACP. (1) · Stephen Luen, MBChB, FRACP. (1) · Tony Penington, MBBS, FRACS. (1)